Fangjian Guo, Victor Adekanmbi, Christine D Hsu, Thao N Hoang, Pamela T Soliman, Jacques G Baillargeon, Abbey B Berenson
{"title":"2001年至2021年美国绝经前和绝经后妇女子宫内膜癌发病率趋势","authors":"Fangjian Guo, Victor Adekanmbi, Christine D Hsu, Thao N Hoang, Pamela T Soliman, Jacques G Baillargeon, Abbey B Berenson","doi":"10.3390/cancers17061035","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Endometrial cancer incidence has been rising in the United States. We assessed trends in endometrial cancer incidence among both premenopausal and postmenopausal women in the US from 2001 to 2021. We also compared the incidence during 2019-2021 to assess the impact of the COVID-19 pandemic.</p><p><strong>Methods: </strong>We used data from the United States Cancer Statistics 2001-2021 database to assess the incidence trends among adult females. Endometrial cancer incidence was corrected for hysterectomy prevalence and age, adjusted to the 2000 US standard population.</p><p><strong>Results: </strong>From 2001 to 2021, the incidence of endometrial cancer rose from 86.8 cases to 113.8 cases per 1,000,000 persons among women aged 20-49 years (APC 1.5, 95% CI 1.2-1.8), while in women 70 and older, it increased from 1326.4 cases to 1339.4 cases per 1,000,000 persons (APC 0.3, 95% CI 0.1-0.6). The incidence has recently decreased among women aged 50-69 years (APC from 2001 to 2016 0.3, 95% CI 0.1-0.9; APC from 2016 to 2021 -1.3, 95% CI -2.2--0.3). Endometrial cancer incidence sharply increased from 2001 to 2021 among non-Hispanic Blacks, non-Hispanic Asians or Pacific Islanders, and women in the South. Endometrial cancer incidence sharply decreased from 2019 to 2020, and the proportion of metastatic cancer at diagnosis increased across all age groups. In 2021, the incidence returned to 2019 levels.</p><p><strong>Conclusions: </strong>Endometrial cancer incidence rates are rising, particularly among premenopausal women. During the beginning of the COVID-19 pandemic, the incidence rates decreased, but the proportion of metastatic cancer increased.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941290/pdf/","citationCount":"0","resultStr":"{\"title\":\"Trends in Endometrial Cancer Incidence Among Premenopausal and Postmenopausal Women in the United States Between 2001 and 2021.\",\"authors\":\"Fangjian Guo, Victor Adekanmbi, Christine D Hsu, Thao N Hoang, Pamela T Soliman, Jacques G Baillargeon, Abbey B Berenson\",\"doi\":\"10.3390/cancers17061035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Endometrial cancer incidence has been rising in the United States. We assessed trends in endometrial cancer incidence among both premenopausal and postmenopausal women in the US from 2001 to 2021. We also compared the incidence during 2019-2021 to assess the impact of the COVID-19 pandemic.</p><p><strong>Methods: </strong>We used data from the United States Cancer Statistics 2001-2021 database to assess the incidence trends among adult females. Endometrial cancer incidence was corrected for hysterectomy prevalence and age, adjusted to the 2000 US standard population.</p><p><strong>Results: </strong>From 2001 to 2021, the incidence of endometrial cancer rose from 86.8 cases to 113.8 cases per 1,000,000 persons among women aged 20-49 years (APC 1.5, 95% CI 1.2-1.8), while in women 70 and older, it increased from 1326.4 cases to 1339.4 cases per 1,000,000 persons (APC 0.3, 95% CI 0.1-0.6). The incidence has recently decreased among women aged 50-69 years (APC from 2001 to 2016 0.3, 95% CI 0.1-0.9; APC from 2016 to 2021 -1.3, 95% CI -2.2--0.3). Endometrial cancer incidence sharply increased from 2001 to 2021 among non-Hispanic Blacks, non-Hispanic Asians or Pacific Islanders, and women in the South. Endometrial cancer incidence sharply decreased from 2019 to 2020, and the proportion of metastatic cancer at diagnosis increased across all age groups. In 2021, the incidence returned to 2019 levels.</p><p><strong>Conclusions: </strong>Endometrial cancer incidence rates are rising, particularly among premenopausal women. During the beginning of the COVID-19 pandemic, the incidence rates decreased, but the proportion of metastatic cancer increased.</p>\",\"PeriodicalId\":9681,\"journal\":{\"name\":\"Cancers\",\"volume\":\"17 6\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941290/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/cancers17061035\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17061035","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:子宫内膜癌在美国的发病率一直在上升。我们评估了2001年至2021年美国绝经前和绝经后妇女子宫内膜癌发病率的趋势。我们还比较了2019-2021年期间的发病率,以评估COVID-19大流行的影响。方法:我们使用2001-2021年美国癌症统计数据库的数据来评估成年女性的发病率趋势。子宫内膜癌的发病率根据子宫切除术的患病率和年龄进行校正,并根据2000年美国标准人口进行校正。结果:从2001年到2021年,20-49岁女性子宫内膜癌发病率从86.8例/ 100万人上升到113.8例/ 100万人(APC 1.5, 95% CI 1.2-1.8),而70岁及以上女性子宫内膜癌发病率从1326.4例/ 100万人上升到1339.4例/ 100万人(APC 0.3, 95% CI 0.1-0.6)。最近50-69岁女性的发病率有所下降(2001年至2016年APC为0.3,95% CI为0.1-0.9;2016年至2021年APC为-1.3,95% CI为-2.2- 0.3)。从2001年到2021年,非西班牙裔黑人、非西班牙裔亚洲人或太平洋岛民以及南方妇女的子宫内膜癌发病率急剧上升。从2019年到2020年,子宫内膜癌发病率急剧下降,诊断时转移性癌症的比例在所有年龄组中都有所增加。2021年,发病率恢复到2019年的水平。结论:子宫内膜癌的发病率正在上升,尤其是绝经前妇女。在COVID-19大流行开始期间,发病率下降,但转移性癌症的比例上升。
Trends in Endometrial Cancer Incidence Among Premenopausal and Postmenopausal Women in the United States Between 2001 and 2021.
Background: Endometrial cancer incidence has been rising in the United States. We assessed trends in endometrial cancer incidence among both premenopausal and postmenopausal women in the US from 2001 to 2021. We also compared the incidence during 2019-2021 to assess the impact of the COVID-19 pandemic.
Methods: We used data from the United States Cancer Statistics 2001-2021 database to assess the incidence trends among adult females. Endometrial cancer incidence was corrected for hysterectomy prevalence and age, adjusted to the 2000 US standard population.
Results: From 2001 to 2021, the incidence of endometrial cancer rose from 86.8 cases to 113.8 cases per 1,000,000 persons among women aged 20-49 years (APC 1.5, 95% CI 1.2-1.8), while in women 70 and older, it increased from 1326.4 cases to 1339.4 cases per 1,000,000 persons (APC 0.3, 95% CI 0.1-0.6). The incidence has recently decreased among women aged 50-69 years (APC from 2001 to 2016 0.3, 95% CI 0.1-0.9; APC from 2016 to 2021 -1.3, 95% CI -2.2--0.3). Endometrial cancer incidence sharply increased from 2001 to 2021 among non-Hispanic Blacks, non-Hispanic Asians or Pacific Islanders, and women in the South. Endometrial cancer incidence sharply decreased from 2019 to 2020, and the proportion of metastatic cancer at diagnosis increased across all age groups. In 2021, the incidence returned to 2019 levels.
Conclusions: Endometrial cancer incidence rates are rising, particularly among premenopausal women. During the beginning of the COVID-19 pandemic, the incidence rates decreased, but the proportion of metastatic cancer increased.
期刊介绍:
Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.